A small proof-of-concept study comparing 17 long-term Vipassana meditators with 17 age- and sex-matched non-meditating controls found differences in blood DNA methylation at several genes previously linked to Alzheimer's disease, including one specific site within APOE. The work, led by researchers in Spain, was first posted as a preprint on bioRxiv in November 2025 and has since been published in the peer-reviewed journal Mindfulness.
The study used a candidate-gene approach, not a genome-wide scan. Researchers measured methylation at 19 CpG sites across seven genes, ABCA7, ADAM10, APOE, HOXA3, NXN, TREM2 and TREML2, that the same research group had earlier flagged as part of a blood-based panel intended to help predict Alzheimer's risk. Blood was drawn from experienced meditators, recruited through the Spanish Association of Mindfulness and a university mindfulness program, and from control volunteers with similar lifestyles, between 2013 and 2014. The meditators were then retested after completing a one-month, largely silent Vipassana retreat.
At baseline, average methylation was higher in meditators than in controls for ADAM10, APOE, HOXA3 and TREM2. For APOE specifically, overall methylation averaged 97.15 percent in meditators versus 96.30 percent in controls, a statistically significant difference; but of the four individual APOE CpG sites tested, only one, a site on chromosome 19 the authors label APOE_CpG4, drove that difference. After the retreat, the researchers also reported a significant drop in ABCA7 methylation and continued elevation in ADAM10 and HOXA3 relative to controls.
The authors describe their own findings in cautious terms, repeatedly calling the work a proof of concept and noting the sample size is limited. They suggest that because the direction of change in ADAM10 and HOXA3 ran opposite to patterns reported in Alzheimer's-affected tissue elsewhere, the shifts could in theory reflect a protective epigenetic signal, a hypothesis the paper itself does not test. No cognitive testing, brain imaging, or clinical follow-up was part of this study, and participants were not randomly assigned to meditate; those who already practiced simply volunteered.